Compare iShares Gold Trust (IAU) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Novartis AG — how do they compare? iShares Gold Trust trades at $83.17, while Novartis AG trades at $152.6 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while iShares Gold Trust pays none, and Novartis AG is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.
| IAU | NVS | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $168.62 |
52-Week Low | $62.49 | $119.31 |
Market Cap | — | $295.37B |
Enterprise Value | — | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU, the iShares Gold Trust ETF, is trading at $83.305, up 0.96% with a bullish technical signal overall. The ETF benefits from gold's recent momentum as spot gold approaches $4,430/oz amid cooling inflation data and geopolitical tensions. Moving averages show bullish alignment while oscillators indicate some overbought conditions. Recent news highlights gold's safe-haven appeal with institutional buying and positive price forecasts.
The outlook remains positive given gold's role as an inflation hedge and safe-haven asset, supported by central bank demand and favorable CPI data. Risks include potential Fed policy shifts and dollar strength. Conservative investors favor IAU for its low 0.25% expense ratio and lower volatility compared to mining equities.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
